Eva Boratto

Partnered with the CEO following the Aetna 2018 acquisition to drive long-term growth by leveraging unique portfolio of assets, capturing greater share of wallet, and reducing costs. Key member of executive team directing company strategy, financial planning, investments, and business objectives. Lead spokesperson with Wall Street. Supported Board by identifying and mitigating financial/shareholder risk scenarios. Team: 5,000. • Met or exceeded all financial metrics provided to investors despite COVID: Synergies 20% above target and 12 months ahead of schedule. • Developed and executed post-acquisition growth plan expected to achieve double-digit EPS increase in 2022. • Paid down $15B in debt and on track to meet low 3x adjusted debt/EBITDA in 2022, down from 4.7x in 2018. Achieved improved outlook from both Moody’s and S&P. • Appointed by the CEO and CHRO to lead supplier diversity task force, resulting in CVS Health’s $1B commitment to diverse supplier spending.

Member, CVS Health Executive Committee, business partner to Chief Operating Officer, and member, Red Oak Board (generic product contracting venture between Cardinal Health and CVS Health). Reported to CFO managing accounting, reporting, financial planning, and Pharmacy Services segment underwriting. Also responsible for all operations related to billing and collections. In 2017, responsibilities expanded to include Retail/Long-Term Care 3rd party relations strategy, and contract negotiation for ~$80B+ revenue. Team: 2,200. • Built enterprise-shared financial services and implemented multi-year strategy to establish a captive “greenfield” service delivery location with over 600 FTEs. Results realized annual run-rate savings of $18M, improvements in collection rate to over 95%, and reduced accounts receivable by ~$200M. • Improved financial planning processes for Pharmacy Services segment resulting in improved cash forecasting, unlock of $100M+ working capital, and improved accuracy of annual planning. • Implemented SAP HANA across closing and consolidation, planning, and inventory. Transitioned from multiple legacy systems to establish common chart of accounts, standardized processes, and “one version of the truth.” Changes enabled earlier access to financial information, enhanced forecasting, and achieved greater transparency.

Member, Caremark Executive Committee. Oversaw all financial aspects for $70B division, including establishing improved financial planning processes, client underwriting, financial operations, and M&A analysis. Team: ~1,000. • Developed long-range strategic business & financial planning process to better understand outlook of business and drive improved resource allocation. • Supported 2011 $1.4B acquisition/integration of Universal American Med D PDP program.

Member, U.S. Market Executive Leadership Team with financial oversight for $15B U.S. Pharmaceutical Market (post-merger of Merck/Schering-Plough, 2009). Charged with integrating organizations to realize synergy targets. Team: 200. • Led roadmap for integration of U.S. financial organizations across ~5 locations. Aligned financial policies, developed integrated financial reporting and business planning processes, and integrated government price and rebate payment.

Member, Finance Senior Leadership Team. Led all interactions with institutional investment community. • Effectively developed and communicated strategic value of Schering-Plough merger with Merck, resulting in four sell-side upgrades and stock appreciation of 67% post-merger.

Member, Finance Executive Committee. Established financial support model for newly integrated Global Pharmaceutical franchises (a combined revenue $22B) while continuing to support $13B U.S. market. U.S. market role expanded to include Customer Contract Management and Order Management Center. Board Member of TeleRx.

Held financial oversight for $10B U.S. Human Health division, including financial reporting & planning, evaluation & analysis of business initiatives, and financial assessment of sales & marketing performance. Team of 55.

Responsible for financial oversight for $1.1B global Vaccine division and $1.5B European joint venture with Aventis Pasteur.